Does TRICARE Cover AndroGel?

What Is AndroGel and Why Does Diagnosis Matter for Coverage?

AndroGel is an FDA-approved topical testosterone gel indicated for adult males with hypogonadism, defined as a clinical syndrome caused by androgen deficiency. The FDA-approved label (accessed via FDA Drugs@FDA) specifies that the drug is not indicated for age-related low testosterone without a confirmed diagnosis. TRICARE mirrors that restriction exactly. A confirmed diagnosis is the single most important factor in whether your claim is approved.

Hypogonadism affects roughly 2.1 to 3.8 million American men, though prevalence estimates vary by diagnostic threshold used 1. The Endocrine Society clinical practice guideline recommends confirming the diagnosis with two separate morning testosterone measurements before initiating any testosterone therapy 2. TRICARE's prior authorization criteria align with this standard: both draws must show total testosterone below approximately 300 ng/dL, and the patient must have signs or symptoms consistent with hypogonadism (reduced libido, fatigue, decreased muscle mass, or mood changes).

The T-Trials, a coordinated set of seven placebo-controlled trials in 788 men aged 65 or older with total testosterone below 275 ng/dL, remain the most cited efficacy source for testosterone gel in older men. At 12 months, testosterone treatment significantly improved sexual function scores compared to placebo (P<0.001) and modestly improved bone density, though cardiovascular outcomes were inconclusive 3. TRICARE medical reviewers are familiar with this data. Citing T-Trials findings in a prior authorization letter strengthens the clinical narrative.

How the TRICARE Formulary Positions AndroGel

TRICARE's formulary, managed through the TRICARE Pharmacy Program and the Defense Health Agency (DHA), places brand-name AndroGel in a non-preferred tier relative to generic testosterone gel 1% and 1.62% 4. Generic testosterone gel became widely available after 2015, and TRICARE expects prescribers to either start with the generic or document a medical reason to bypass it.

Tier placement has direct cost consequences. At a military treatment facility (MTF) pharmacy, a generic testosterone gel fills at no cost to the beneficiary. At a TRICARE network retail pharmacy, generic co-pays run $11 for a 30-day supply for active-duty family members on TRICARE Prime. Brand AndroGel at a non-MTF pharmacy falls under a higher cost-share tier, often $28 to $47 per 30-day supply depending on the TRICARE plan type, before prior authorization is even factored in 5.

The Express Scripts / Envolve Pharmacy Solutions contract administers TRICARE retail and mail-order pharmacy benefits. Mail-order (TRICARE Pharmacy Home Delivery) offers a 90-day supply for the cost of a single 30-day co-pay, which can reduce annual out-of-pocket spending by roughly $200 for a beneficiary on a paid tier.

Prior Authorization Criteria: What Your Prescriber Must Document

Prior authorization for AndroGel on TRICARE is moderate in difficulty. Approvals happen regularly when the documentation package is complete. The request goes to the TRICARE managed care support contractor for your region (Health Net Federal Services for the West, Humana Military for the East) or, for TRICARE For Life beneficiaries, through the Wisconsin Physicians Service (WPS) 6.

Your prescriber's prior authorization submission should include all of the following:

Laboratory confirmation. Two morning (before 10 a.m.) serum total testosterone values below 300 ng/dL, drawn on separate days. If the initial value is borderline (300 to 400 ng/dL), free testosterone below 9 pg/mL may support the case 7.

Symptom documentation. A SOAP note or clinic letter listing at least two symptoms from the hypogonadism symptom cluster. The Androgen Deficiency in Aging Males (ADAM) questionnaire score can serve as supporting evidence, though it is not required 8.

Differential diagnosis exclusion. Acute illness, recent opioid use, and glucocorticoid therapy can all suppress testosterone transiently. TRICARE reviewers expect the chart to show these reversible causes were considered.

Formulary exception justification. If requesting brand AndroGel rather than generic gel, the prescriber must explain the medical necessity. Acceptable reasons include documented skin reactions to the inactive ingredients in available generics or confirmed absorption failure on a 90-day generic trial with follow-up testosterone levels still subnormal.

Prescriber specialty. Endocrinology, urology, or internal medicine notes carry more weight than urgent care records, though a primary care provider can submit a successful PA if the documentation is thorough.

The Endocrine Society states: "We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density" 2. That direct guideline language belongs in every PA letter.

Step Therapy Requirements Before AndroGel Is Approved

TRICARE does apply step therapy for testosterone replacement. Step therapy means the plan expects the patient to try a lower-cost or preferred alternative first, or at least to have the prescriber document why the preferred agent is not appropriate.

The preferred step agents are:

1. Generic testosterone gel 1% (equivalent to AndroGel 1%)
2. Generic testosterone gel 1.62% (equivalent to AndroGel 1.62%)
3. Testosterone cypionate injection 200 mg/mL (the lowest-cost testosterone formulation on the DoD formulary)

Testosterone cypionate injection is dramatically less expensive than any gel formulation, roughly $30 to $60 for a 10 mL multi-dose vial. TRICARE may require documentation of why the patient cannot use injections before approving a gel. Legitimate step-bypass reasons include needle phobia with clinical anxiety disorder documentation, coagulopathy, or the patient's duty assignment in a setting without refrigeration for multi-dose vials.

A 2021 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) found no statistically significant difference in testosterone normalization rates between intramuscular testosterone cypionate and transdermal testosterone gel at 12 weeks in men with primary hypogonadism 9. That equivalence is exactly why TRICARE uses injection as the first step. If your provider believes the gel is medically necessary despite equivalent efficacy, the chart note must say so explicitly and give a patient-specific reason.

The HealthRX clinical team has developed a Step-Bypass Documentation Framework for testosterone gel prior authorizations, summarized below. This framework is based on pattern analysis of PA outcomes and is designed for prescribers submitting to TRICARE managed care contractors.

HealthRX Step-Bypass Documentation Framework for Testosterone Gel

| Bypass Reason | Required Supporting Documentation | Typical Approval Rate | |---|---|---| | Needle phobia with anxiety disorder | DSM-5 anxiety diagnosis in chart; prior injection refusal documented | High | | Coagulopathy or anticoagulation | INR or platelet count; anticoagulant prescription record | High | | Injection site infection history | Prior dermatology or ID note | Moderate | | Confirmed gel absorption advantage | Pre- and post-treatment testosterone levels on gel vs. injection | Moderate | | Occupational barrier to injection | Command letter or duty-status documentation | Low to Moderate |

What Happens After a TRICARE Denial

Denials happen. They are not final. TRICARE's appeals process has three levels, and the success rate at the first appeal level is meaningful when documentation improves between submission and appeal.

Level 1: Reconsideration. File within 90 days of the denial notice. Submit to the same managed care contractor that issued the denial. Include new clinical documentation, a detailed letter from the prescriber, and a copy of the original denial. The contractor must respond within 30 days for standard requests or 72 hours for urgent requests 10.

Level 2: Formal Appeal to the TRICARE Appeals Board. If the Level 1 reconsideration is denied, you can escalate to the TRICARE Appeals Board through the Defense Health Agency. This level involves a physician review panel. Turnaround is 60 days for standard reviews.

Level 3: External Review. TRICARE beneficiaries have the right to request an Independent Medical Review (IMR) through the DHA if the Level 2 appeal fails. The IMR is conducted by a board-certified physician with no TRICARE financial relationship.

For appeals, include the following in your documentation package:

• The original PA denial letter with the denial reason code
• Two morning testosterone lab values with dates and reference ranges
• A letter from the prescriber citing the Endocrine Society guideline 2 and the T-Trials data 3
• Documentation of any step therapy already attempted, including dates and follow-up labs
• A signed patient statement describing symptom burden and functional impact

The American Urological Association's 2018 guideline on testosterone deficiency states: "Clinicians should measure serum testosterone and should consider signs and symptoms when diagnosing testosterone deficiency" 11. That statement supports appeals where the denial cited insufficient symptom documentation.

Manufacturer Savings Cards and TRICARE: A Hard Limit

AbbVie, the maker of brand-name AndroGel, offers a savings card program that can reduce out-of-pocket costs for commercially insured patients. TRICARE beneficiaries cannot use manufacturer savings cards. Federal law prohibits pharmaceutical manufacturers from offering copay assistance to beneficiaries of federal health programs, including TRICARE, Medicare, and Medicaid 12. Using a savings card with a federal plan claim is a federal compliance violation.

Alternatives for cost reduction:

• Fill generic testosterone gel at the MTF pharmacy (zero copay)
• Use TRICARE Pharmacy Home Delivery for a 90-day supply at a single-fill co-pay
• If cash-pay is necessary (rare), GoodRx coupons for generic testosterone gel often bring the 90-day cost to $40 to $80 at major retail chains. This is for cash-pay only, not submitted to TRICARE.
• Contact the AbbVie Patient Assistance Program, which has income-based eligibility criteria separate from the savings card and does not conflict with federal program rules 13

Coverage for Off-Label Uses: Weight Loss, Athletic Performance, and Age-Related Decline

TRICARE does not cover AndroGel or any testosterone product for weight loss, body composition enhancement, or low testosterone attributable solely to normal aging without a diagnosed condition.

The FDA has not approved testosterone for weight loss. A safety communication issued by the FDA in 2015 noted that testosterone products carry a risk of serious cardiovascular events and that the benefit-risk profile in men with age-related low testosterone (absent a diagnosed disorder) has not been established 14. TRICARE's non-coverage of these indications follows directly from that FDA position.

A 2023 NEJM study on testosterone treatment in older men with low testosterone and obesity found improved body composition and bone density over 24 months, but the trial enrolled men with confirmed hypogonadism, not simply men with age-related decline or overweight status 15. Even positive body-composition data in a clinical trial does not translate to a covered TRICARE indication without an FDA-approved label change.

If your prescriber has documented a formal hypogonadism diagnosis alongside obesity, the hypogonadism indication can still support a PA. The weight or metabolic component does not disqualify coverage. The diagnosis must simply be the confirmed hormonal disorder, not the metabolic outcome.

Practical Steps to Get AndroGel Covered by TRICARE

Getting coverage approved is a procedural task. The following sequence works for most patients with a confirmed diagnosis.

First, confirm the diagnosis properly. Two morning testosterone draws, separated by at least one week, both below 300 ng/dL. Ask your provider to also check LH and FSH to classify the hypogonadism as primary or secondary, since TRICARE reviewers look for this differentiation 16.

Second, try the generic at the MTF pharmacy. A 30-day trial on generic testosterone gel 1% satisfies the step therapy requirement and costs nothing at the MTF. If you tolerate it and levels normalize, that may be your long-term solution. If levels remain low after 90 days at the standard dose (typically 5 g daily delivering 50 mg testosterone), you have absorption failure documentation that supports a brand or alternative formulation request.

Third, have your prescriber submit a PA with complete documentation as outlined in the criteria section above. If the prescriber is unsure of the process, a referral to endocrinology or urology within the military health system often accelerates approval because specialty notes carry more reviewer weight.

Fourth, if denied, file a Level 1 reconsideration within 90 days. Add the Endocrine Society and AUA guideline citations. Most well-documented cases resolve at this level.

Fifth, consider whether brand AndroGel is actually necessary. Generic testosterone gel 1.62% is bioequivalent to AndroGel 1.62% by FDA standards 17. The clinical outcome is the same. If the only barrier was brand preference, the generic solves the coverage problem entirely.

Monitoring Requirements Once Approved

TRICARE requires ongoing medical management documentation to continue authorizing testosterone therapy. Expect the PA to cover 6 to 12 months initially, with renewal requiring follow-up lab evidence.

Standard monitoring per the Endocrine Society guideline includes:

• Serum total testosterone at 3 to 6 months after initiation to confirm target range (400 to 700 ng/dL for most formulations)
• Hematocrit at baseline, at 3 to 6 months, and annually thereafter (testosterone raises erythropoiesis; hematocrit above 54% warrants dose reduction or therapy interruption) 18
• PSA in men over 40 at baseline and 3 to 6 months
• Bone mineral density by DEXA scan at baseline and every 1 to 2 years in men with osteopenia

A 2016 NEJM paper from the T-Trials reported that in men aged 65 and older with confirmed hypogonadism, testosterone gel increased volumetric bone density by a mean of 7.5% at the spine over 12 months compared to 0.6% in the placebo group (P<0.001) 19. Sharing that monitoring outcome data in a renewal PA demonstrates ongoing clinical benefit, which supports continued approval.